

1 **Plasma biomarker profiles and the correlation with cognitive function across the**
2 **clinical spectrum of Alzheimer's disease**

3

4 Zhenxu Xiao^{1,2†}, Xue Wu^{3†}, Wanqing Wu^{1,2}, Jingwei Yi³, Xiaoniu Liang^{1,2}, Saineng
5 Ding^{1,2}, Li Zheng^{1,2}, Jianfeng Luo^{4,5}, Hongchen Gu³, Qianhua Zhao^{1,2*}, Hong Xu^{3*},
6 Ding Ding^{1,2}

7

8 ¹ *Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China;*

9 ² *National Clinical Research Center for Aging and Medicine, Huashan Hospital,*

10 *Fudan University, Shanghai, China;*

11 ³ *School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai,*

12 *China;*

13 ⁴ *Department of Biostatistics, School of Public Health, Fudan University, Shanghai,*

14 *China;*

15 ⁵ *Key Lab of Public Health Safety of the Ministry of Education, Fudan University,*

16 *Shanghai, China.*

17

18

19

20 * Correspondence to: Qianhua Zhao, Institute of Neurology, Huashan Hospital, Fudan

21 University, 12 Wulumuqi Zhong Rd., Shanghai 200040, China;

22 qianhuazhao@fudan.edu.cn

23 or Hong Xu, School of Biomedical Engineering, Shanghai Jiao Tong University,

24 Shanghai, China; xuhong@sjtu.edu.cn

25 † Zhenxu Xiao and Xue Wu contributed equally to this article.

26 **Abstract**

27 **Background** Plasma biomarkers showed a promising value in the disease diagnosis
28 and management of Alzheimer's disease (AD). However, profiles of the biomarkers
29 and the association with cognitive domains along the spectrum of cognitive
30 performance deterioration have seldom been reported.

31 **Methods** We recruited 320 individuals with cognitive impairment and 131 cognitively
32 normal participants from a memory clinic and a community cohort. Participants were
33 classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and
34 clinical diagnosis of AD, amnesic mild cognitive impairment, and normal cognition
35 (NC). Each participant was administered the neuropsychological tests assessing the
36 global and domain-specific cognition. Plasma $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}/A\beta_{1-40}$, total tau
37 (t-tau), neurofilament protein light chain (NfL), and phosphorylated tau at threonine
38 181 (p-tau181) were quantified using the Single molecule array platform.

39 **Results** Along with plasma $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}/A\beta_{1-40}$, t-tau, and NfL, p-tau181
40 significantly increased across the groups with the incremental CDR scores from NC
41 (CDR = 0) to severe AD (CDR = 3). Compared with other biomarkers, p-tau181 had a
42 stronger correlation with Global cognition ($r = -0.494$, $P < 0.001$), Memory ($r =$
43 -0.417 , $P < 0.001$), Attention ($r = -0.388$, $P < 0.001$), Visuospatial function ($r = -0.328$,
44 $P < 0.001$), and Language ($r = -0.123$, $P = 0.014$). Among AD participants with CDR
45 ≥ 1 , higher p-tau181 was correlated with worse Global cognition ($r = -0.295$, $P <$
46 0.001), Memory ($r = -0.172$, $P = 0.045$), and Attention ($r = -0.184$, $P = 0.031$).

47 **Conclusions** Plasma p-tau181 had a stronger correlation with cognitive domains than
48 other biomarkers, especially in late-stage AD. It could reflect the AD pathology in
49 vivo and may be a promising blood-based biomarker in clinical settings.

50 **Key words** Plasma p-tau181, Simoa, cognitive domain, CDR, Alzheimer's disease

51 **Background**

52 Alzheimer's disease (AD), the most common cause of dementia, is characterized
53 by the accumulation of the amyloid plaques and neuronal tangles in the brain [1].
54 Previous AD-relevant biomarkers could only be detected in the cerebrospinal fluid
55 (CSF) or through positron emission tomography (PET) [1]. With the development of
56 ultrasensitive immunoassays technique, detecting AD relevant biomarkers in blood
57 samples became available [2]. Plasma biomarkers have a promising value in clinic
58 usage due to the non-invasiveness, cost-effectiveness, and easy accessibility [3].
59 Following $A\beta_{1-42}$, $A\beta_{1-40}$, total tau (t-tau), neurofilament protein light chain (NfL),
60 recently reported plasma phosphorylated tau at threonine 181 (p-tau181) showed
61 better diagnostic performance and prognostic value in several cohort studies [3-9].

62 The cognitive performance is a pivotal indicator in AD management and efficacy
63 evaluation. Previous studies found plasma $A\beta_{1-42}$ [10], NfL [11, 12], and p-tau181 [3,
64 4, 13] were significantly different in participants with mild cognitive impairment
65 (MCI) and AD compared with participants with normal cognition (NC). However, few
66 studies depicted plasma biomarkers' profiles based on the cognitive performance and
67 compared their discrepancy during the entire course of AD. It would be valuable to
68 depict the trajectory of different plasma AD biomarkers from NC until the severe
69 cognitive impairment stage since the cognitive manifestations are the most concerned
70 issues for both clinicians, patients, and the caregivers.

71 In addition, some studies investigated the relationships between plasma
72 biomarkers and various cognitive domains [14-23]. However, they only focused on
73 individual markers, and the results were incomparable or inconsistent due to the
74 diverse testing platforms and study designs. It is also worthwhile to observe which
75 biomarker has the best correlation with diverse cognitive domains.

76 In this study, we aimed to observe the trajectory of the plasma biomarkers profile,
77 including $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}/A\beta_{1-40}$, t-tau, NfL, and p-tau181, across the clinical
78 spectrum of AD evaluated with the clinical dementia rating (CDR) scale. We also
79 intended to explore the correlation between these biomarkers and the domain-specific
80 cognitive function, especially in different clinical AD stages.

81

82 **Methods**

83 **Study participants**

84 Participants with cognitive impairment were consecutively recruited from the
85 memory clinic of the department of neurology, Huashan Hospital, Shanghai, China
86 from November 2018 to September 2020. The inclusion criteria included: (1)
87 consulted at the memory clinic due to memory complaints from herself (himself) or
88 proxy; (2) able to cooperate with physical examinations and neuropsychological tests;
89 (3) diagnosed with single-domain amnesic MCI (aMCI-s), multi-domain amnesic
90 MCI (aMCI-m), or AD; (4) consent to the blood draw.

91 Participants in the Shanghai Aging Study (SAS) were eligible to be selected as
92 the controls with NC. The SAS is a community-based longitudinal cohort in
93 downtown Shanghai, China. The original purpose of SAS was to investigate the
94 prevalence, incidence and risk factors for dementia and MCI among older residents in
95 an urban community. The detailed study design and recruitment procedure have been
96 published elsewhere [24]. In this study, the participants were selected from the third
97 wave of follow-up between Jun and Oct in 2020 if they were: (1) 60 years or older; (2)

98 able to cooperate with physical examinations and neuropsychological tests; (3)

99 diagnosed with NC; (4) consent to the blood draw.

100

101 **Demographics and assessment of covariables**

102 The demographic and lifestyle characteristics were acquired from the participants
103 and/or proxy through a questionnaire. The educational background was defined as the
104 years of formal education. Participants who smoked daily within the past month were
105 regarded as cigarette smoking, and participants who had one serving of alcohol
106 weekly during the past year were defined as alcohol consumption [25]. Hypertension
107 and diabetes mellitus were confirmed by the medical records [24].

108 Apolipoprotein E (APOE) genotype was assessed by the Taqman single
109 nucleotide polymorphism method using the blood or saliva samples collected from the
110 participants [26]. The presence of at least one APOE ϵ 4 allele was regarded as APOE
111 ϵ 4 positive.

112

113 **Neuropsychological tests**

114 Comprehensive neuropsychological tests were administered by the certified
115 psychometrists. All the tests were translated and adapted from western countries
116 harmonized to Chinese culture, and were validated in Chinese population. Each
117 participant from the memory clinic received a battery of neuropsychological tests,
118 including: (1) Mini-Mental Status Examination (MMSE) [27]; (2) Montreal Cognitive
119 Assessment-Basic (MoCA-B) [28-30]; (3) Auditory Verbal Learning Test [31, 32]; (4)

120 Symbol Digit Modalities Test [33, 34]; (5) Rey-Osterrieth Complex Figure test [34];
121 (6) Boston Naming Test [35]; (7) Trail Making Test (TMT) [36]. For those who
122 refused or were unable to complete the whole battery of tests, only MMSE and
123 MoCA-B were administered. As for the participants with NC, a battery of similar
124 neuropsychological tests was administered [31]: (1) MMSE [27]; (2) Auditory Verbal
125 Learning Test [31, 32]; (3) Conflicting Instructions Task (Go/No-Go Task) [31]; (4)
126 Stick Test [31]; (5) Modified Common Objects Sorting Test [31]; (6) TMT [36].

127 We extracted raw scores from above-mentioned neuropsychological tests to
128 evaluate five clinically relevant cognitive domains including Memory, Attention,
129 Visuospatial function, Language, and Executive function (Supplementary Table 1).
130 Z-scores ($Z = (\text{raw score} - \text{mean}) / \text{standard deviation}$) of domains were computerized
131 for analysis.

132

133 **Cognitive impairment severity and consensus diagnosis**

134 All participants and their proxy were interviewed by two neurologists specialized
135 in neurodegenerative diseases. The CDR, a semi-structured inventory, was used to
136 assess the severity of cognitive impairment. It covered six cognitive, behavior, and
137 function aspects, including memory, orientation, judgment and problem solving,
138 community affairs, home and hobbies performance, and personal care. The
139 neurologists scored on each aspect, taking into consideration information collected
140 from both participants and proxy. The global CDR score was calculated automatically
141 on biostat.wustl.edu/~adrc/cdrpgm/index.html by inputting in each CDR box score,

142 based on the Washington University CDR-assignment algorithm with a 0-3 scale
143 index [37, 38].

144 Neurologists and neuropsychologists reached a consensus diagnosis of the
145 cognitive function of each participant. The presence or absence of dementia was
146 defined using the DSM- \square criteria [39]. AD was diagnosed according to the
147 NINCDS-ADRDA criteria [40]. The diagnosis of MCI was based on Petersen's
148 criteria [41]: (1) cognitive complaint by the subject, informant, nurse, or physician,
149 with CDR = 0.5; (2) objective impairment in at least 1 cognitive domain. (3)
150 essentially normal functional activities (determined from the CDR and the Activities
151 of Daily Living evaluation); and (4) absence of dementia [42]. Because aMCI is more
152 likely to progress to AD [43], we only included participants with 2 types of aMCI: (1)
153 aMCI-s, memory impairment was required with no deficit in other domains; (2)
154 aMCI-m, memory impairment plus at least 1 additional deficit in another domain. NC
155 participants had no memory complaint and have been confirmed cognitively intact
156 through detailed neuropsychological assessment. For participants from memory clinic,
157 laboratory tests and MR scan were performed to rule out the secondary causes related
158 to cognitive impairment.

159 In this study, the continuum of AD was described based on the combination of
160 CDR and the cognitive diagnosis: NC (CDR = 0), aMCI-s (CDR = 0.5), aMCI-m
161 (CDR = 0.5), mild AD (CDR = 1), moderate AD (CDR = 2), and severe AD (CDR = 3)
162 [37, 38].

163

164 **Plasma biomarkers measurement**

165 Blood samples were collected in Ethylene Diamine Tetraacetic Acid (EDTA)
166 plasma tubes and centrifuged (1,000 rpm, 4 °C) for 15 min. After the centrifugation,
167 plasma was transferred into 1.5ml Eppendorf tubes and stored at -80°C
168 refrigerators.

169 Plasma $\text{A}\beta_{1-40}$, $\text{A}\beta_{1-42}$, t-tau, NfL, and p-tau181 were quantified using an
170 ultra-sensitive Single molecule array (Simoa) (Quanterix, MA, US) on the automated
171 Simoa HD-X platform per manufacturer's instruction. The multiplex Neurology
172 3-Plex A kits (Cat. No. 101995), NF-light assay (Cat. No. 103186), and p-tau181
173 Assay Kit V2 (Cat. No.103714) were purchased from Quanterix and used accordingly.
174 Technicians who performed the assay were blinded to the clinical data.

175

176 **Statistical Analyses**

177 Mean and standard deviation (SD) were used to describe normally distributed
178 continuous variables, while the median and quartile 1 (Q1) to quartile 3 (Q3) were
179 used to describe the skewed distributed continuous variables. For categorical variables,
180 number (n) and frequencies (%) were employed. One-way Analyses of Variance
181 (ANOVA) and Kruskal-Wallis tests were used for comparing continuous variables,
182 and Pearson Chi-square and Fisher exact tests were used to compare the categorical
183 variables. For the comparisons among multi-groups, ANOVA and post hoc Tukey
184 multiple comparison tests were used for variables with equal variance, while Welch
185 and post hoc Games-Howell tests were used for variables with unequal variance.

186 Boxplots and points were used to present the distributions of original values of
187 six plasma biomarkers. Levene's tests were used for testing the homogeneity of
188 variances in six groups with different cognition status. Associations between
189 domain-specific Z scores and log-transformed plasma biomarker indexes (due to
190 non-normal distributions [3]) were examined using partial Pearson correlation
191 analyses with the adjustment for confounding variables. The heatmap matrix was
192 implemented to visualize the adjusted partial correlation coefficients r in all
193 participants. Positive correlations ($r > 0$) were exhibited in red, and negative
194 correlations ($r < 0$) were exhibited in blue in the heatmap figure. The same correlation
195 analyses were applied to participants with CDR = 0, CDR = 0.5, and CDR ≥ 1 ,
196 respectively.

197 Two-sided $P < 0.05$ was considered statistically significant. Data were
198 analyzed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk,
199 N.Y., USA) [44] and R (version 4.0.2) [45]. Box plots were produced using the
200 package ggplot2 in R. The heatmap was visualized by GraphPad Prism version 8.0.0
201 for Windows, GraphPad Software, San Diego, California USA (www.graphpad.com).

202

203 **Results**

204 **Characteristics of the study participants**

205 We recruited 451 participants, including 320 participants from the memory clinic
206 cohort and 131 NC participants from the community cohort. The characteristics of
207 study participants were shown in Table 1. Significant difference was found in gender
208 ($P = 0.011$), age ($P < 0.001$), education years ($P < 0.001$), and APOE $\epsilon 4$ allele ($P <$

209 0.001) among six cognitive performance groups. The most severe
210 cognitive-impairment group (CDR = 3) had the highest proportion of women (68.4 %),
211 the lowest mean age (mean = 62.3), the shortest education years (mean = 5.6), and the
212 largest proportion of positive APOE ϵ 4 allele (57.9 %). We did not find the significant
213 discrepancy in smoking, alcohol consumption, hypertension, and diabetes mellitus
214 among six groups. All Neuropsychological tests' scores were significantly different
215 among six groups (all $P < 0.001$).

216

217 **Plasma biomarkers across groups with different cognitive performance**

218 As shown in Figure 1, plasma $A\beta_{1-40}$, $A\beta_{1-42}$, and $A\beta_{1-42}/A\beta_{1-40}$ ratio showed a
219 descending trend, while plasma t-tau, NfL, and p-tau181 exhibited an increasing trend
220 across groups with the increasing CDR scores in general. With regard to $A\beta_{1-40}$, $A\beta_{1-42}$
221 and NfL, we found significant differences between participants with NC (CDR = 0)
222 and AD (CDR \geq 1) (Figure 1 A, B and E). $A\beta_{1-42}/A\beta_{1-40}$, and t-tau showed differences
223 only between participants with NC (CDR = 0) and severe AD (CDR = 3) (Figure 1 C
224 and D). There was no significant discrepancy of $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}/A\beta_{1-40}$, t-tau, or
225 NfL among participants with different severity level of AD (CDR = 1, 2, or 3).
226 P-tau181 gradually increased across the AD cognitive continuum, with the lowest
227 concentration in NC participants (CDR = 0), an increase in participants with aMCI
228 (CDR = 0.5), and the highest concentration in participants with AD (CDR \geq 1) (Figure
229 1 F). Specifically, participants with severe AD (CDR = 3) had significantly higher
230 p-tau181 than those with mild AD (CDR = 1).

231

232 **Correlation between plasma biomarkers and domain-specific cognition**

233 Figure 2 showed the partial correlation matrix between six plasma biomarkers and

234 six domain-specific cognitions after adjusting age, gender, education years, and APOE.
235 $A\beta_{1-40}$ was only correlated positively with Memory ($r = 0.125$, $P = 0.012$). $A\beta_{1-42}$ was
236 correlated positively with MMSE ($r = 0.119$, $P = 0.012$), Memory ($r = 0.203$, $P <$
237 0.001), and Attention ($r = 0.104$, $P = 0.036$), while $A\beta_{1-42}/A\beta_{1-40}$ was correlated
238 positively with Memory ($r = 0.114$, $P = 0.022$) and Attention ($r = 0.100$, $P = 0.044$).
239 T-tau had an inverse correlation with MMSE ($r = -0.154$, $P = 0.001$), Memory ($r =$
240 -0.146 , $P = 0.003$), and Attention ($r = -0.116$, $P = 0.020$). Higher NFL was correlated
241 with worse MMSE ($r = -0.298$, $P < 0.001$), Memory ($r = -0.263$, $P < 0.001$), Attention
242 ($r = -0.209$, $P < 0.001$), Visuospatial function ($r = -0.236$, $P < 0.001$), and Language (r
243 $= -0.105$, $P < 0.036$). P-tau181 showed a stronger correlation inversely with MMSE (r
244 $= -0.497$, $P < 0.001$), Memory ($r = -0.417$, $P < 0.001$), Attention ($r = -0.388$, $P <$
245 0.001), Visuospatial function ($r = -0.328$, $P < 0.001$), but a weaker correlation with
246 Language ($r = -0.123$, $P = 0.014$).

247 As shown in Table 2, no significant correlation was found between plasma
248 biomarkers and cognitive domain scores in NC participants. Among aMCI
249 participants with CDR = 0.5, higher $A\beta_{1-42}/A\beta_{1-40}$ was correlated with the
250 deterioration of MMSE ($r = -0.209$, $P = 0.011$) and Executive function ($r = -0.197$, P
251 $= 0.021$). Higher NfL was correlated with worse Visuospatial function ($r = -0.174$, $P =$
252 0.045), and higher p-tau181 was correlated with worse Memory ($r = -0.167$, $P =$
253 0.048).

254 As for the AD participants with $CDR \geq 1$, plasma $A\beta_{1-42}$ had positive correlation
255 only with Memory ($r = 0.184$, $P = 0.030$), and $A\beta_{1-42}/A\beta_{1-40}$ had positive correlation
256 with MMSE ($r = 0.156$, $P = 0.046$) and Attention ($r = 0.187$, $P = 0.028$). Increased
257 plasma NfL was only correlated with worse Executive function ($r = -0.171$, $P =$
258 0.048). Higher p-tau181 was correlated with worse MMSE ($r = -0.295$, $P < 0.001$),

259 Memory ($r = -0.172$, $P = 0.045$), and Attention ($r = -0.184$, $P = 0.031$).

260 **Discussion**

261 The present study demonstrated that plasma $A\beta_{1-40}$, $A\beta_{1-42}$, and $A\beta_{1-42}/A\beta_{1-40}$ had
262 a decreasing trend, while plasma t-tau, NfL, and p-tau181 escalated along the
263 deterioration of the cognitive performance. P-tau181 was the best indicator of clinical
264 cognitive performance and had a stronger correlation with global and other cognitive
265 domains than other five AD biomarkers. To our knowledge, it was the first study to
266 exhibit the distribution of plasma p-Tau 181 using the Simoa HD-X platform in
267 Chinese older individuals along the clinical AD continuum.

268 Pathology is pivotal in the diagnosis of AD. However, cognitive performance,
269 including various cognitive domains, played a more significant role in patient
270 management and efficacy evaluation. Cognitive manifestations are closely related to
271 one's daily function and quality of life for both patients and caregivers. Thus, we
272 focused on individual's performance, and classified the participants into six groups
273 according to CDR levels and clinical cognitive diagnosis. One previous study found
274 plasma p-tau181 increased at preclinical AD and further increased at the MCI and
275 dementia stages [3]. Another group verified that plasma p-tau181 gradually increased
276 from the $A\beta$ -negative cognitively unimpaired older adults, through the $A\beta$ -positive
277 cognitively unimpaired and MCI groups, to the highest concentrations in $A\beta$ -positive
278 MCI and AD groups [4]. Our results testified their findings from the clinical
279 perspective and further indicated that p-tau181 was a symptom-related plasma
280 biomarker. Although some AD markers showed a significant escalating or descending

281 trend along the whole disease continuum, plasma p-tau181 is the only one that had the
282 significant discrepancy in the later stage of AD with overt dementia symptoms. This
283 means plasma p-tau181 may keep increasing along with the deterioration of cognitive
284 function, till the most severe stage of AD. Previous studies showed that plasma
285 p-tau181 was correlated with CSF p-tau181 in AD patients, suggesting that plasma
286 p-tau181 was originated from the central nervous system [3, 4]. Peripheral p-tau
287 reflects the phosphorylation of the tau protein, which eventually leads to the
288 neurofibrillary tangles in the brain [8]. Therefore, the continuous increment of the
289 plasma p-tau across different stages of AD indicated the ongoing tau-related
290 pathologic change in the brain, even in the late stage of the disease. This may
291 potentially guide the development of disease-modifying therapy for terminal-stage
292 patients in the future.

293 One subset cohort in a study demonstrated that plasma p-tau181 was correlated
294 with baseline MMSE [4]. However, the relationships between plasma p-tau181 and
295 different cognitive domains have not been reported. Our study revealed a strong
296 correlation between plasma p-tau181 and AD-related cognitive domains. The
297 correlations between p-tau181 and MMSE, Memory, and Attention were only
298 observed in participants with dementia symptoms. This phenomenon may mainly
299 reflect the fact that plasma p-tau181 is regulated differently by the disease staging,
300 namely the Alzheimer's pathological status in the brain. Another possibility is that, the
301 narrow range of testing scale weakens the correlation of plasma biomarkers with
302 cognition, due to "ceiling effects" or "floor effects" of the tests. However, this might

303 not be the major explanation, because when analyzing with the more sensitive
304 neuropsychological tests assessing Memory and Attention, the correlations were still
305 not be observed in the subgroup with CDR = 0.

306 The NfL was an age-related biomarker [46]. Lin et. al. found that higher plasma
307 NfL levels correlated with lower MMSE scores [15]. However, they did not adjust for
308 age in the correlation analysis. The results from Chatterjee et. al. showed that plasma
309 NfL was inversely correlated with working memory, executive function, and the
310 global composite score after considering the age [14]. Two studies found plasma NfL
311 associated with all cognitive domains after adjusting potential confounders including
312 age [22, 23]. However, using the same Simoa detecting method, a Chinese group did
313 not find any correlation of NfL with episodic memory, information processing speed,
314 executive function, or visuospatial function after adjusting for age, gender, and
315 education. In our results, the plasma NfL had a significant correlation after adjustment
316 for age and other covariates, not only with global cognition, but also with the other
317 four cognitive domains. This suggested that, although NfL was regarded as a
318 non-specific biomarker for neurological diseases [12], it still has value in the
319 monitoring of AD cognitive deterioration. However, many correlations could not be
320 observed when we classified participants into three groups according to CDR levels of
321 0, 0.5, and ≥ 1 . The paradoxical results may reflect the underlying diverse
322 pathophysiological conditions in different cognitive status [46].

323 The traditional amyloid cascade theory emphasized that A β as an initial factor
324 triggers the following Tau pathology [1]. However, the plasma amyloid biomarkers

325 ($A\beta_{1-42}$, $A\beta_{1-40}$, $A\beta_{1-42}/A\beta_{1-40}$) in our study had a relatively weaker correlation only
326 with MMSE, Memory, and Attention. Previous CSF and PET studies [47, 48]
327 indicated that, the amyloid-related biomarkers reflected the earliest pathological
328 change but tended to reach a plateau as the disease progressed to the dementia stage.
329 Since the plasma $A\beta$ level was supposed to reflect the central nervous change [49],
330 blood $A\beta$ level may also be saturated in the symptomatic individuals. However, in the
331 CDR subgroups, the trend is ambiguous and inconsistent, probably because of the
332 small sample size. Further large-sampled longitudinal studies need to be conducted to
333 demonstrate the dynamic of plasma $A\beta$ levels along the clinical spectrum of AD. A
334 previous experimental study showed that neurons exposed to $A\beta$ had increased
335 synthesis and secretion of tau [50]. These neurons may eventually degenerate and
336 develop tangle pathology, which may also drive the increase of p-tau in the blood.
337 Therefore, regarding AD as a whole disease continuum, plasma p-tau181, as a more
338 sensitive and clinical-relevant blood-based biomarker, may be superior to $A\beta$.

339

340 **Limitations**

341 There are several limitations in our study. Firstly, the biomarkers in this study
342 were only detected once without longitudinal measurements. However, we separated
343 the participants into six groups according to CDR scores and cognitive diagnosis to
344 simulate the AD spectrum. Future prospective studies are needed to verify our
345 findings. Secondly, the participants in our studies were from two different resources
346 with unavoidable imparity. However, there was no significant difference in some

347 dementia-related risk factors, such as smoking, alcohol consumption, hypertension,
348 and diabetes mellitus (Table 1). Age, gender, education year, and APOE were
349 adjusted in the multivariate statistical models. Thirdly, some neuropsychological tests
350 might have “ceiling effects” (e.g. Go/No-Go Task) or “floor effects” (e.g. Auditory
351 Verbal Learning Test), which may conceal the relationship between the biomarkers
352 and the cognitive domains. Lastly, we diagnosed AD based on the clinical standard
353 rather than pathological evidence of CSF or amyloid/tau PET. Lacking a golden
354 standard impeded us from the classifying of “ATN” framework [51] or Receiver
355 Operating Characteristic analysis.

356

357 **Conclusions**

358 In conclusion, we found plasma p-tau181 increased along the clinical continuum
359 of AD. Plasma p-tau181 had a stronger correlation with cognitive domains than other
360 biomarkers, especially in late-stage AD. Our study suggests that the plasma p-tau181
361 could reflect the AD pathology in vivo and may be a promising blood-based
362 biomarker in clinical settings. Longitudinal studies are needed to verify these findings
363 and provide more evidence of the association between plasma p-tau181 and clinical
364 cognitive manifestations.

365

366 **Abbreviations**

367 AD: Alzheimer’s disease; aMCI: amnesic mild cognitive impairment; aMCI-m:
368 amnesic mild cognitive impairment multi-domains; aMCI-s: amnesic mild cognitive

369 impairment single-domain; ANOVA: Analysis of Variance; APOE: Apolipoprotein E;
370 CDR: Clinical Dementia Rating; CSF: cerebrospinal fluid; EDTA: Ethylene Diamine
371 Tetraacetic Acid; MCI: mild cognitive impairment; MMSE: Mini-mental State
372 Examination; MoCA-B: Montreal Cognitive Assessment-Basic; NC: normal cognition;
373 NfL: neurofilament protein light chain; PET: positron emission tomography; p-tau181:
374 phosphorylated tau 181; SAS: Shanghai Aging Study; SD: standard deviation; Simoa:
375 Single molecule array; TMT: Trail Making Test; t-tau: total tau.

376

377 **Acknowledgements**

378 Not applicable

379

380 **Authors' contributions**

381 QZ, HX, and DD developed the original idea. ZX and XW searched the literature. ZX,
382 WW, XL, SD, and LZ collected samples and data. XW and JY measured the blood
383 biomarkers with support from HG. ZX and JL analyzed data. ZX and XW wrote the
384 manuscript. QZ, HX, and DD revised the manuscript. All authors read and approved
385 the final manuscript.

386

387 **Funding**

388 This work was supported by grants of Clinical Research Plan of SHDC (No.
389 SHDC2020CR4007), Key projects of special development funds for Shanghai
390 Zhangjiang National Innovation Demonstration Zone (201905-XH-CHJ-H25-201),

391 MOE Frontiers Center for Brain Science (JH2642001/028), Scientific Research Plan
392 Project of Shanghai Science and Technology Committee (17411950106,
393 17411950701), National Project of Chronic Disease (2016YFC1306402), National
394 Natural Science Foundation of China (82071200, 81773513, 21874091, 31927803),
395 and Shanghai Municipal Science and Technology Major Project (2018SHZDZX01)
396 and ZJLab.

397

398 **Availability of data and materials**

399 The datasets used and/or analyzed during the current study are available from the
400 corresponding author on reasonable request.

401

402 **Ethics approval and consent to participate**

403 This study was approved by the Medical Ethics Committee of Huashan Hospital,
404 Fudan University, Shanghai, China (No. 2009-195 and 2011-288). All participants
405 and/or their legal proxy gave written informed consent to participate.

406

407 **Consent for publication**

408 Not applicable

409

410 **Competing interests**

411 The authors declare that they have no competing interests.

412

413 **Author details**

414 ¹Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China;

415 ²National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan

416 University, Shanghai, China; ³School of Biomedical Engineering, Shanghai Jiao Tong

417 University, Shanghai, China; ⁴Department of Biostatistics, School of Public Health,

418 Fudan University, Shanghai, China; ⁵Key Lab of Public Health Safety of the Ministry

419 of Education, Fudan University, Shanghai, China.

420

421 **References**

422 1. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al.

423 Alzheimer's disease. *Lancet* (London, England). 2016;388(10043):505-17.

424 2. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and

425 prospects for the future. *J Intern Med*. 2018;284(6):643-63.

426 3. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma

427 P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis,

428 neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*.

429 2020;26(3):379-86.

430 4. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood

431 phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance

432 and prediction modelling study using data from four prospective cohorts. *The Lancet*

433 *Neurology*. 2020;19(5):422-33.

434 5. Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, et al.

- 435 Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior
436 to post-mortem and improves the clinical characterisation of cognitive decline. *Acta*
437 *Neuropathol.* 2020;140(3):267-78.
- 438 6. Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized
439 prognosis of cognitive decline and dementia in mild cognitive impairment based on
440 plasma biomarker combinations. *Nature Aging.* 2020;1(1):114-23.
- 441 7. Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, et al. Plasma tau/amyloid-beta1-42
442 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *Brain.*
443 2019;142(3):771-86.
- 444 8. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181
445 increases with Alzheimer's disease clinical severity and is associated with tau- and
446 amyloid-positron emission tomography. *Alzheimers Dement.* 2018;14(8):989-97.
- 447 9. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau
448 isoforms track CNS change in Alzheimer's disease. *J Exp Med.*
449 2020;217(11):e20200861.
- 450 10. Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, et al. Plasma A β 42 as a
451 Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild
452 Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. *J Alzheimers Dis.*
453 2019;69(1):37-48.
- 454 11. Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels
455 in Alzheimer's disease. *Neurosci Lett.* 2017;650:60-4.
- 456 12. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma

- 457 Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA*
458 *Neurol.* 2017;74(5):557-66.
- 459 13. Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M,
460 et al. Diagnostic performance and prediction of clinical progression of plasma
461 phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. *Mol Psychiatry.*
462 2021;26(2):429-42.
- 463 14. Chatterjee P, Goozee K, Sohrabi HR, Shen K, Shah T, Asih PR, et al. Association of
464 Plasma Neurofilament Light Chain with Neocortical Amyloid-beta Load and Cognitive
465 Performance in Cognitively Normal Elderly Participants. *J Alzheimers Dis.*
466 2018;63(2):479-87.
- 467 15. Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and
468 cognitive function in patients with Alzheimer or Parkinson disease. *Sci Rep.*
469 2018;8(1):17368.
- 470 16. Shi Y, Lu X, Zhang L, Shu H, Gu L, Wang Z, et al. Potential Value of Plasma Amyloid-beta,
471 Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. *ACS*
472 *Chem Neurosci.* 2019;10(8):3479-85.
- 473 17. Lee JJ, Choi Y, Chung S, Yoon DH, Choi SH, Kang SM, et al. Association of Plasma
474 Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of
475 Consortium to Establish a Registry for Alzheimer's Disease in Health Screening
476 Population. *Diagnostics (Basel).* 2020;10(4):237.
- 477 18. Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, et al. Plasma
478 Amyloid-beta Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's

- 479 Disease. *J Alzheimers Dis.* 2020;77(3):1057-65.
- 480 19. Tsai CL, Liang CS, Lee JT, Su MW, Lin CC, Chu HT, et al. Associations between Plasma
481 Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnesic Mild
482 Cognitive Impairment: A Cross-Sectional and Longitudinal Study. *J Clin Med.*
483 2019;8(11):1893.
- 484 20. Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels
485 in Alzheimer's disease. *Neurosci Lett.* 2017;650:60-4.
- 486 21. Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A
487 longitudinal examination of plasma neurofilament light and total tau for the clinical
488 detection and monitoring of Alzheimer's disease. *Neurobiol Aging.* 2020;94:60-70.
- 489 22. Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al.
490 Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly
491 associates with cerebral amyloid pathology. *Alzheimers Res Ther.* 2020;12(1):118.
- 492 23. Dage JL, Wennberg AMV, Airey DC, Hagen CE, Knopman DS, Machulda MM, et al.
493 Levels of tau protein in plasma are associated with neurodegeneration and cognitive
494 function in a population-based elderly cohort. *Alzheimers Dement.* 2016;12(12):1226-34.
- 495 24. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Yu P, et al. The Shanghai Aging Study: study
496 design, baseline characteristics, and prevalence of dementia. *Neuroepidemiology.*
497 2014;43(2):114-22.
- 498 25. Luo J, Zhu G, Zhao Q, Guo Q, Meng H, Hong Z, et al. Prevalence and risk factors of poor
499 sleep quality among Chinese elderly in an urban community: results from the Shanghai
500 aging study. *PLoS One.* 2013;8(11):e81261.

- 501 26. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of
502 radiation-induced changes in human gene expression. *Nature*. 2009;459(7246):587-91.
- 503 27. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, et al. The prevalence of
504 dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and
505 education. *Ann Neurol*. 1990;27(4):428-37.
- 506 28. Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, et al. Validation of the
507 Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive
508 Impairment. *J Am Geriatr Soc*. 2016;64(12):e285-e90.
- 509 29. Huang L, Chen KL, Lin BY, Tang L, Zhao QH, Lv YR, et al. Chinese version of Montreal
510 Cognitive Assessment Basic for discrimination among different severities of Alzheimer's
511 disease. *Neuropsychiatr Dis Treat*. 2018;14:2133-40.
- 512 30. Huang YY, Qian SX, Guan QB, Chen KL, Zhao QH, Lu JH, et al. Comparative study of
513 two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive
514 Impairment. *Appl Neuropsychol Adult*. 2019:1-6.
- 515 31. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, et al. Prevalence of mild cognitive
516 impairment in an urban community in China: a cross-sectional analysis of the Shanghai
517 Aging Study. *Alzheimers Dement*. 2015;11(3):300-9 e2.
- 518 32. Zhao Q, Lv Y, Zhou Y, Hong Z, Guo Q. Short-term delayed recall of auditory verbal
519 learning test is equivalent to long-term delayed recall for identifying amnesic mild
520 cognitive impairment. *PLoS One*. 2012;7(12):e51157.
- 521 33. Guo Q, Zhao Q, Chen M, Ding D, Hong Z. A comparison study of mild cognitive
522 impairment with 3 memory tests among Chinese individuals. *Alzheimer Dis Assoc Disord*.

- 523 2009;23(3):253-9.
- 524 34. Zhou B, Zhao Q, Kojima S, Ding D, Higashide S, Nagai Y, et al. One-year Outcome of
525 Shanghai Mild Cognitive Impairment Cohort Study. *Curr Alzheimer Res.*
526 2019;16(2):156-65.
- 527 35. Weixiong S, Chuanzhen LV, Yimin S, Lv CZ, Guo QH. Boston naming test in Chinese
528 elderly: patient with mild cognitive impairment and Alzheimer s dementia. *Chinese Mental*
529 *Health J.* 2006;20:81-84.
- 530 36. Lu J, Guo Q, Hong Z, Shi W, Lu C. Trail making test used by Chinese elderly patients with
531 mild cognitive impairment and mild Alzheimer's dementia. *Chinese J Clin Psychol.*
532 2006;14:118-21.
- 533 37. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.
534 *Neurology.* 1993;43(11):2412-4.
- 535 38. Lim WS, Chong MS, Sahadevan S. Utility of the clinical dementia rating in Asian
536 populations. *Clin Med Res.* 2007;5(1):61-70.
- 537 39. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders,
538 ed 4. Washington, American Psychiatric Association, 1994, p. 143-147.
- 539 40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
540 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the
541 auspices of Department of Health and Human Services Task Force on Alzheimer's
542 Disease. *Neurology.* 1984;34(7):939-44.
- 543 41. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.*
544 2004;256(3):183-94.

- 545 42. Petersen RC. Clinical practice. Mild cognitive impairment. *New Engl J Med.*
546 2011;364(23):2227-34.
- 547 43. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E
548 and donepezil for the treatment of mild cognitive impairment. *New Engl J Med.*
549 2005;352(23):2379-88.
- 550 44. IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY:
551 IBM Corp.
- 552 45. R Core Team (2020). R: A language and environment for statistical computing. R
553 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- 554 46. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament
555 light chain as a biomarker in neurological disorders. *J Neurol Neurosurg Psychiatry.*
556 2019;90(8):870-81.
- 557 47. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β
558 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a
559 prospective cohort study. *The Lancet Neurology.* 2013;12(4):357-67.
- 560 48. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H. Correlation between cognitive
561 impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's
562 disease. *J Alzheimers Dis.* 2010;22(3):971-80.
- 563 49. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al.
564 Amyloid beta concentrations and stable isotope labeling kinetics of human plasma
565 specific to central nervous system amyloidosis. *Alzheimers Dement.* 2017;13(8):841-9.
- 566 50. Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer's disease.

567 Nat Neurosci. 2020;23(10):1183-93.

568 51. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA

569 Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers*

570 *Dement.* 2018;14(4):535-62.

Table 1. Demographic characteristics and the neuropsychological assessments among study participants

	Total (N = 451)	Clinical diagnosis						<i>P</i> value
		NC CDR = 0 (N = 131)	aMCI-s CDR = 0.5 (N = 39)	aMCI-m CDR = 0.5 (N = 113)	Mild AD CDR = 1 (N = 67)	Moderate AD CDR = 2 (N = 102)	Severe AD CDR = 3 (N = 38)	
<i>Demographic characteristics</i>								
Gender, female, n (%)	260 (57.6)	82 (62.6)	14 (35.9)	69 (61.1)	31 (46.3)	38 (61.9)	26 (68.4)	0.011
Age, y, mean (SD)	68.6 (8.8)	69.2 (7.1)	69.6 (9.3)	70.0 (8.0)	67.7 (9.7)	69.1 (9.8)	62.3 (8.2)	<0.001
Education years, mean (SD)	10.3 (4.1)	11.8 (2.9)	13.6 (3.6)	10.2 (3.6)	10.3 (3.6)	8.4 (4.0)	5.6 (4.0)	<0.001
Smoking, n (%)	79 (17.5)	17 (13.0)	5 (12.8)	23 (20.4)	15 (22.4)	12 (18.9)	7 (18.4)	0.529
Alcohol consumption, n (%)	77 (17.1)	19 (14.5)	4 (10.3)	21 (18.6)	18 (26.9)	12 (18.9)	3 (7.9)	0.139
Hypertension, n (%)	168 (37.3)	53 (40.5)	17 (43.6)	44 (38.9)	23 (34.3)	22 (34.3)	9 (23.7)	0.461
Diabetes mellitus, n (%)	68 (15.1)	19 (14.5)	7 (17.9)	19 (16.8)	8 (11.9)	10 (15.6)	5 (13.2)	0.933
APOE ε4 positive, n (%)	161 (35.7)	13 (9.9)	12 (30.8)	48 (42.5)	30 (44.8)	36 (55.8)	22 (57.9)	<0.001
<i>Neuropsychological tests</i>								
MMSE score, mean (SD)	23.3 (6.7)	29.0 (1.3)	27.7 (1.7)	25.8 (1.9)	21.9 (1.4)	15.5 (3.5)	7.4 (2.6)	<0.001
Memory*, median [Q1, Q3]	-0.07 [-1.18, 0.72]	0.87 [0.56, 1.50]	0.16 [-0.23, 0.72]	-0.23 [-0.71, 0.72]	-0.71 [-1.18, -0.23]	-1.18 [-1.18, -0.82]	-1.18 [-1.18, -1.18]	<0.001
Execution function*, median [Q1, Q3]	0.43 [-1.25, 0.43]	0.43 [0.43, 0.43]	0.43 [0.43, 1.49]	-0.41 [-1.25, 1.28]	0.43 [-1.25, 0.43]	-1.25 [-1.25, -0.41]	-1.25 [-1.25, -1.25]	<0.001
Attention*, median [Q1, Q3]	0.43 [-0.39, 0.83]	0.83 [0.67, 0.83]	0.69 [0.40, 0.83]	0.43 [-0.21, 0.83]	-0.36 [-0.78, 0.43]	-1.41 [-0.99, -0.39]	-2.01 [-2.42, -2.01]	<0.001
Language*, median [Q1, Q3]	0.58 [-0.27, 0.72]	0.72 [0.58, 0.72]	0.58 [0.16, 0.72]	-0.27 [-0.66, 0.72]	-0.27 [-1.16, 0.72]	-0.26 [-0.26, 0.72]	-1.26 [-2.25, -0.27]	<0.001
Visuospatial function*, median [Q1, Q3]	0.31 [-0.63, 0.93]	0.93 [0.62, 0.93]	0.76 [0.31, 0.93]	0.15 [-0.32, 0.62]	-0.63 [-1.25, -0.005]	-1.27 [-0.87, -0.32]	-1.87 [-2.18, -1.02]	<0.001

Note: * Z score transformed. NC, normal cognition; aMCI-s, amnesic mild cognitive impairment-single domain; aMCI-m, amnesic mild cognitive impairment-multiple domains; AD, Alzheimer's disease; CDR, Clinical Dementia Rating Scale; SD, standard deviation; Q1, quartile 1; Q3, quartile 3; APOE, apolipoprotein E; MMSE, mini-mental state examination.

medRxiv preprint doi: <https://doi.org/10.1101/2021.02.05.21251241>; this version posted February 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Figure 1. Plasma biomarkers in participants with different clinical cognitive status.

Note: The ANOVA and the post hoc Tukey test were used for comparison of plasma $A\beta_{1-40}$ & $A\beta_{1-42}$ in six groups, while Welch test and the post hoc Games-Howell test were used to compare the plasma $A\beta_{1-42}/A\beta_{1-40}$, t-tau, NfL, p-tau181 among six groups. Six extreme values were not shown in panel E, but they were included in the statistical analyses. *P* values are presented with asterisks: * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001, **** *P* < 0.0001. NC, normal cognition; aMCI-s, amnesic mild cognitive impairment-single domain; aMCI-m, amnesic mild cognitive impairment-multiple domains; AD, Alzheimer's disease; CDR, Clinical Dementia Rating Scale; $A\beta$, amyloid-beta protein; t-tau, total tau; NfL, neurofilament protein light chain; p-tau181, tau phosphorylated at threonine 181.

Figure 2. Correlations between plasma biomarkers and cognitive domains.

Note: The plasma biomarkers concentrations were log transformed. The Pearson correlation coefficients (*r*) were adjusted for age, gender, education year, and APOE. $A\beta$, amyloid-beta protein; t-tau, total tau; NfL, neurofilament protein light chain; p-tau181, tau phosphorylated at threonine 181.

Table 2. Correlations between plasma biomarkers and global & domain-specific cognition in participants with different AD stages

Biomarkers	Global (MMSE)						Memory						Attention					
	CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		CDR ≥ 1	
	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
Plasma Aβ ₁₋₄₀	-0.105	0.256	0.097	0.240	-0.032	0.681	-0.088	0.350	0.048	0.574	0.083	0.331	-0.094	0.311	-0.052	0.542	-0.060	0.480
Plasma Aβ ₁₋₄₂	-0.086	0.350	-0.109	0.188	0.067	0.394	-0.023	0.805	0.148	0.080	0.184	0.030	-0.169	0.068	-0.020	0.814	0.038	0.659
Plasma Aβ ₁₋₄₂ /Aβ ₁₋₄₀	-0.023	0.804	-0.209	0.011	0.156	0.046	0.028	0.767	0.127	0.135	0.112	0.190	-0.122	0.190	-0.013	0.877	0.187	0.028
Plasma t-tau	-0.008	0.933	-0.108	0.193	-0.132	0.092	-0.182	0.051	-0.151	0.074	-0.063	0.463	-0.119	0.203	-0.079	0.353	-0.042	0.622
Plasma NfL	-0.168	0.067	-0.052	0.530	-0.129	0.104	0.048	0.610	-0.083	0.330	-0.158	0.067	-0.053	0.568	-0.026	0.762	0.030	0.732
Plasma p-tau181	-0.011	0.907	-0.076	0.360	-0.295	<0.001	-0.025	0.793	-0.167	0.048	-0.172	0.045	0.068	0.467	0.005	0.949	-0.184	0.031

Biomarkers	Visuospatial function						Language						Executive function					
	CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		CDR ≥ 1	
	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
Plasma Aβ ₁₋₄₀	-0.108	0.250	-0.024	0.785	0.099	0.280	-0.152	0.103	-0.093	0.272	-0.041	0.641	-0.011	0.908	0.041	0.631	-0.002	0.984
Plasma Aβ ₁₋₄₂	-0.004	0.963	-0.149	0.089	0.114	0.217	-0.083	0.375	-0.127	0.133	-0.016	0.904	-0.074	0.442	-0.117	0.169	0.062	0.471
Plasma Aβ ₁₋₄₂ /Aβ ₁₋₄₀	0.092	0.327	-0.131	0.137	0.049	0.593	0.090	0.337	-0.098	0.249	0.036	0.673	-0.092	0.339	-0.197	0.021	0.085	0.322
Plasma t-tau	0.048	0.607	0.117	0.183	-0.102	0.270	-0.007	0.943	-0.058	0.492	-0.025	0.775	0.003	0.973	0.017	0.843	-0.032	0.711
Plasma NfL	-0.047	0.616	-0.174	0.045	0.042	0.652	-0.147	0.115	0.038	0.654	0.007	0.932	0.056	0.558	0.127	0.136	-0.171	0.048
Plasma p-tau181	0.079	0.398	-0.044	0.616	-0.066	0.479	-0.025	0.793	0.071	0.405	0.067	0.438	0.006	0.948	0.133	0.120	-0.060	0.489

Note: The plasma biomarkers concentrations were log transformed. The Pearson correlation coefficients (*r*) were adjusted for age, gender, education year, and APOE ε4. Bold numbers indicate *P* < 0.05.

CDR, Clinical Dementia Rating Scale; Aβ, amyloid-beta protein; t-tau, total tau; NfL, neurofilament protein light chain; p-tau181, tau phosphorylated at threonine 181.

medRxiv preprint doi: <https://doi.org/10.1101/2021.02.05.21251241>; this version posted February 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



